| __timestamp | Apellis Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 24419536 |
| Thursday, January 1, 2015 | 6356782 | 34718089 |
| Friday, January 1, 2016 | 4303743 | 40998209 |
| Sunday, January 1, 2017 | 10463151 | 32022880 |
| Monday, January 1, 2018 | 22639184 | 19110051 |
| Tuesday, January 1, 2019 | 67046483 | 26556257 |
| Wednesday, January 1, 2020 | 139401000 | 52275890 |
| Friday, January 1, 2021 | 176771000 | 80981000 |
| Saturday, January 1, 2022 | 277163000 | 124431000 |
| Sunday, January 1, 2023 | 500815000 | 90932000 |
| Monday, January 1, 2024 | 98761000 |
Unveiling the hidden dimensions of data
In the competitive world of biopharmaceuticals, understanding spending patterns can offer valuable insights into a company's strategic priorities. Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Apellis saw a staggering increase of over 17,000% in SG&A expenses, peaking in 2023. This reflects their aggressive expansion and investment in market presence. In contrast, Arrowhead's SG&A expenses grew by approximately 270% during the same period, indicating a more measured approach. Notably, Apellis's spending surpassed Arrowhead's by over 450% in 2023, highlighting their divergent strategies. However, data for 2024 is incomplete, leaving room for speculation on future trends. These patterns underscore the dynamic nature of the biopharmaceutical industry, where strategic spending can significantly impact market positioning.
Takeda Pharmaceutical Company Limited vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: argenx SE vs Apellis Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Evotec SE
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE